Abstract
Backround
Severe injury leads to a severe deterioration of the patients’ immune response. The changes of the immune response after severe injury include a broad range of immune functions and may result in a status of immunosuppression, which could favor infectious complications. Therefore, immunostimulating therapies have been introduced in the therapy for severely injured patients in clinical and experimental settings.
Objectives
The article summarizes actual immunomodulating approaches in the treatment of trauma patients and therapeutic strategies avoiding additional immune deteriorations.
Results
Examples for an immunostimulating approach in trauma patients are interferonγ and the granulocyte macrophage-colony-stimulating factor (GM-CSF), which are summarized in this review in detail. However, the effect of such an interference in the patients’ immune response with all its different cellular targets is not yet clearly understood, and most studies focus on the reaction of circulating monocytes. In addition, further immunomodulating strategies, including nutritional support, are addressed. However, clinically established therapeutic immunomodulating strategies in trauma care so far do not exist. The impact of the accidental and also an additional surgical trauma on the immune response has been clearly demonstrated. Therefore, the idea of a “damage control orthopedic surgery” (DCOS) is not only necessary to prevent further deterioration of the homeostasis of, e.g., the coagulating system, but is also desirable in terms of minimizing the burden on the immune system. In addition, also the timing of secondary surgical treatment in trauma patient care should include an evaluation of the immune response, although the most reliable markers still need to be identified.
Conclusion
Immunomodulating therapies in trauma patients exist on an experimental level with inconsistent results. The general management of trauma patients includes strategies that have been developed also on the basis of immunological considerations.
Similar content being viewed by others
References
Cavaillon JM, Adrie C, Fitting C, Adib-Conquy M (2005) Reprogramming of circulatory cells in sepsis and SIRS. J Endotoxin Res 11:311–320
Schmand JF, Ayala A, Chaudry IH (1994) Effects of trauma, duration of hypotension, and resuscitation regimen on cellular immunity after hemorrhagic shock. Crit Care Med 22:1076–1083
Zellweger R, Ayala A, DeMaso CM, Chaudry IH (1995) Trauma–hemorrhage causes prolonged depression in cellular immunity. Shock 4:149–153
Flohé S, Ackermann M, Reuter M, Nast-Kolb D, Schade FU (2000) Sublethal hemorrhagic shock reduces tumor necrosis factor-alpha-producing capacity in different cell compartments. Eur Cytokine Netw 11:420–426
Hassoun HT, Kone BC, Mercer DW, Moody FG, Weisbrodt NW, Moore FA (2001) Post-injury multiple organ failure: the role of the gut. Shock 15:1–10
Sori AJ, Rush BF Jr, Lysz TW, Smith S, Machiedo GW (1988) The gut as source of sepsis after hemorrhagic shock. Am J Surg 155:187–192
Moore FA et al (1991) Gut bacterial translocation via the portal vein: a clinical perspective with major torso trauma. J Trauma 31:629–636 discussion 636–638
Rock KL, Hearn A, Chen CJ, Shi Y (2005) Natural endogenous adjuvants. Springer Semin Immunopathol 26:231–246
Hashiguchi N et al (2001) Enhanced expression of heat shock proteins in activated polymorphonuclear leukocytes in patients with sepsis. J Trauma 51:1104–1109
Pespeni M et al (2005) Serum levels of Hsp60 correlate with the development of acute lung injury after trauma. J Surg Res 126:41–47
Flohé SB, Bangen JM, Flohé S, Agrawal H, Bergmann K, Schade FU (2007) Origin of immunomodulation after soft tissue trauma: Potential involvement of extracellular Heat-Shock. Shock 27:494–502
Huber-Lang M et al (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12:682–687
Nast-Kolb D et al (1997) Indicators of the posttraumatic inflammatory response correlate with organ failure in patients with multiple injuries. J Trauma 42:446–454 discussion 454–455
Donnelly TJ et al (1994) Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med 22:768–776
Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Bruckner UB (2000) Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg 135:291–295
Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL (1997) Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 25:1813–1819
Roumen RM et al (1993) Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 218:769–776
Liener UC, Bruckner UB, Knoferl MW, Steinbach G, Kinzl L, Gebhard F (2002) Chemokine activation within 24 hours after blunt accident trauma. Shock 17:169–172
Armstrong L, Millar AB (1997) Relative production of tumour necrosis factor alpha and interleukin 10 in adult respiratory distress syndrome. Thorax 52:442–446
Antonelli M et al (1994) Leukotrienes and alpha tumor necrosis factor levels in the bronchoalveolar lavage fluid of patient at risk for the adult respiratory distress syndrome. Minerva Anestesiol 60:419–426
Giannoudis PV, Smith MR, Evans RT, Bellamy MC, Guillou PJ (1998) Serum CRP and IL-6 levels after trauma. Not predictive of septic complications in 31 patients. Acta Orthop Scand 69:184–188
Pape HC et al (1999) Levels of antibodies to endotoxin and cytokine release in patients with severe trauma: does posttraumatic dysergy contribute to organ failure? J Trauma 46:907–913
DiPiro JT, Howdieshell TR, Goddard JK, Callaway DB, Hamilton RG, Mansberger AR Jr (1995) Association of interleukin-4 plasma levels with traumatic injury and clinical course. Arch Surg 130:1159–1162 discussion 1162–1153
Majetschak M, Boergermann J, Waydhas C, Obertacke U, Nast-Kolb D, Schade FU (2000) Whole blood tumor necrosis factor-alpha production and its relation to systemic concentrations of interleukin 4, interleukin 10, and transforming growth factor-beta1 in multiply injured blunt trauma victims. Crit Care Med 28:1847–1853
Sherry RM, Cue JI, Goddard JK, Parramore JB, DiPiro JT (1996) Interleukin-10 is associated with the development of sepsis in trauma patients. J Trauma 40:613–616 discussion 616–617
Menges T et al (1999) Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications. Crit Care Med 27:733–740
Neidhardt R et al (1997) Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma 42:863–870 discussion 870–871
Faist E et al (1987) Prostaglandin E2 (PGE2)-dependent suppression of interleukin alpha (IL-2) production in patients with major trauma. J Trauma 27:837–848
Miller-Graziano CL, Szabo G, Griffey K, Mehta B, Kodys K, Catalano D (1991) Role of elevated monocyte transforming growth factor beta (TGF beta) production in posttrauma immunosuppression. J Clin Immunol 11:95–102
Ditschkowski M et al (1999) HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg 229:246–254
Livingston DH, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC Jr (1988) Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg 123:1309–1312
Ploder M et al (2006) Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock 25:129–134
Keel M et al (1996) Different pattern of local and systemic release of proinflammatory and anti-inflammatory mediators in severely injured patients with chest trauma. J Trauma 40:907–912 discussion 912–914
Ertel W et al (1995) Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85:1341–1347
Marie C, Muret J, Fitting C, Losser MR, Payen D, Cavaillon JM (1998) Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory response syndrome. Blood 91:3439–3446
Majetschak M et al (1997) Regulation of whole blood tumor necrosis factor production upon endotoxin stimulation after severe blunt trauma. J Trauma 43:880–887
Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM (1991) Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88:1747–1754
Williams MA et al (1998) Granulocyte-macrophage colony-stimulating factor induces activation and restores respiratory burst activity in monocytes from septic patients. J Infect Dis 177:107–115
Volk HD et al (1991) Alterations in function and phenotype of monocytes from patients with septic disease-predictive value and new therapeutic strategies. Behring Inst Mitt:208–215
Volk HD et al (1996) Monocyte deactivation—rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22 Suppl 4:S474–481
Lendemans S, Kreuzfelder E, Waydhas C, Nast-Kolb D, Flohé S (2004) Clinical course and prognostic significance of immunological and functional parameters after severe trauma. Unfallchirurg 107:203–210
Flohé SB, Agrawal H, Schmitz D, Gertz M, Flohé S, Schade FU (2006) Dendritic cells during polymicrobial sepsis rapidly mature but fail to initiate a protective Th1-type immune response. J Leukoc Biol 79:473–481
Hotchkiss RS et al (2002) Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 168:2493–2500
De AK, Laudanski K, Miller-Graziano CL (2003) Failure of monocytes of trauma patients to convert to immature dendritic cells is related to preferential macrophage-colony-stimulating factor-driven macrophage differentiation. J Immunol 170:6355–6362
Meakins JL, McLean AP, Kelly R, Bubenik O, Pietsch JB, MacLean LD (1978) Delayed hypersensitivity and neutrophil chemotaxis: effect of trauma. J Trauma 18:240–247
Christou NV et al (1995) The delayed hypersensitivity response and host resistance in surgical patients. 20 years later. Ann Surg 222:534–546; discussion 546–548
Woltmann A, Kress HG (1991) The prognostic value of the delayed cutaneous immune reaction following multiple trauma in comparison with other clinical parameters. Anaesthesist 40:276–281
Pape HC et al (2000) Biochemical changes after trauma and skeletal surgery of the lower extremity: quantification of the operative burden. Crit Care Med 28:3441–3448
Menger MD, Vollmar B (2004) Surgical trauma: hyperinflammation versus immunosuppression? Langenbecks Arch Surg 389:475–484
Asadullah K et al (1995) Immunodepression following neurosurgical procedures. Crit Care Med 23:1976–1983
Hiesmayr MJ et al (1999) Alterations in the number of circulating leucocytes, phenotype of monocyte and cytokine production in patients undergoing cardiothoracic surgery. Clin Exp Immunol 115:315–323
Decker D, Schondorf M, Bidlingmaier F, Hirner A, von Ruecker AA (1996) Surgical stress induces a shift in the type-1/type-2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to the trauma. Surgery 119:316–325
Mels AK et al (2001) Immune-stimulating effects of low-dose perioperative recombinant granulocyte-macrophage colony-stimulating factor in patients operated on for primary colorectal carcinoma. Br J Surg 88:539–544
Berger D, Bolke E, Seidelmann M, Beger HG (1997) Time-scale of interleukin-6, myeloid related proteins (MRP), C reactive protein (CRP), and endotoxin plasma levels during the postoperative acute phase reaction. Shock 7:422–426
Rotondo MF et al (1993) ‘Damage control’: an approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma 35:375–382 discussion 382–383
Harwood PJ, Giannoudis PV, van Griensven M, Krettek C, Pape HC (2005) Alterations in the systemic inflammatory response after early total care and damage control procedures for femoral shaft fracture in severely injured patients. J Trauma 58:446–452 discussion 452–454
Pape HC et al (2003) Impact of intramedullary instrumentation versus damage control for femoral fractures on immunoinflammatory parameters: prospective randomized analysis by the EPOFF Study Group. J Trauma 55:7–13
Pape H, Stalp M, v Griensven M, Weinberg A, Dahlweit M, Tscherne H (1999) Optimal timing for secondary surgery in polytrauma patients: an evaluation of 4,314 serious-injury cases. Chirurg 70:1287–1293
Waydhas C et al (1996) Posttraumatic inflammatory response, secondary operations, and late multiple organ failure. J Trauma 40:624–630 discussion 630–631
Pape HC et al (2001) Major secondary surgery in blunt trauma patients and perioperative cytokine liberation: determination of the clinical relevance of biochemical markers. J Trauma 50:989–1000
Flohé S, Lendemans S, Schade FU, Kreuzfelder E, Waydhas C (2004) Influence of surgical intervention in the immune response of severely injured patients. Intensive Care Med 30:96–102
Taeger G, Ruchholtz S, Waydhas C, Lewan U, Schmidt B, Nast-Kolb D (2005) Damage control orthopedics in patients with multiple injuries is effective, time saving, and safe. J Trauma 59:409–416 discussion 417
Scalea TM, Boswell SA, Scott JD, Mitchell KA, Kramer ME, Pollak AN (2000) External fixation as a bridge to intramedullary nailing for patients with multiple injuries and with femur fractures: damage control orthopedics. J Trauma 48:613–621 discussion 621–623
Nowotarski PJ, Turen CH, Brumback RJ, Scarboro JM (2000) Conversion of external fixation to intramedullary nailing for fractures of the shaft of the femur in multiply injured patients. J Bone Joint Surg Am 82:781–788
Nast-Kolb D, Ruchholtz S, Waydhas C, Schmidt B, Taeger G (2005) Damage control orthopedics. Unfallchirurg 108(804):806–811
Ertel W, Morrison MH, Ayala A, Dean RE, Chaudry IH (1992) Interferon-gamma attenuates hemorrhage-induced suppression of macrophage and splenocyte functions and decreases susceptibility to sepsis. Surgery 111:177–187
Hershman MJ, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC, Jr (1989) Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clin Exp Immunol 77:67–70
Polk HC, Jr et al (1992) A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am J Surg 163:191–196
Dries DJ et al (1994) Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. Arch Surg 129:1031–1041 discussion 1042
Turina M, Dickinson A, Gardner S, Polk HC, Jr (2006) Monocyte HLA-DR and interferon-gamma treatment in severely injured patients—a critical reappraisal more than a decade later. J Am Coll Surg 203:73–81
Hayes MP, Enterline JC, Gerrard TL, Zoon KC (1991) Regulation of interferon production by human monocytes: requirements for priming for lipopolysaccharide-induced production. J Leukoc Biol 50:176–181
Lendemans S, Rani M, Selbach C, Kreuzfelder E, Schade FU, Flohé S (2006) GM-CSF priming of human monocytes is dependent on ERK1/2 activation. J Endotoxin Res 12:10–20
Flohé S et al. (2003) Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma. Crit Care Med 31:2462–2469
Fischer HG, Frosch S, Reske K, Reske-Kunz AB (1988) Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol 141:3882–3888
Flohé S et al (1999) Influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) on whole blood endotoxin responsiveness following trauma, cardiopulmonary bypass, and severe sepsis. Shock 12:17–24
Bilgin K, Yaramis A, Haspolat K, Tas MA, Gunbey S, Derman O (2001) A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 107:36–41
Nierhaus A et al (2003) Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 29:646–651
Wiltschke C, Krainer M, Nanut M, Wagner A, Linkesch W, Zielinski CC (1995) In vivo administration of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor increases neutrophil oxidative burst activity. J Interferon Cytokine Res 15:249–253
Hartung T et al (1995) Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 85:2482–2489
Schneider C, von Aulock S, Zedler S, Schinkel C, Hartung T, Faist E (2004) Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann Surg 239:75–81
Schaefer H et al (2004) Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: a randomized placebo-controlled clinical trial. Ann Surg 240:68–75
Heard SO et al (1998) Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. The Filgrastim Study Group. Crit Care Med 26:748–754
Jeschke MG, Herndon DN (2004) Effect of growth factors as therapeutic drugs on hepatic metabolism during the systemic inflammatory response syndrome. Curr Drug Metab 5:399–413
Fukushima R et al (1999) Prophylactic treatment with growth hormone and insulin-like growth factor I improve systemic bacterial clearance and survival in a murine model of burn-induced gut-derived sepsis. Burns 25:425–430
Huang Y, Wang SR, Yi C, Ying MY, Lin Y, Zhi MH (2002) Effects of recombinant human growth hormone on rat septic shock with intraabdominal infection by E. coli. World J Gastroenterol 8:1134–1137
Takala J et al (1999) Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341:785–792
Wu JC, Livingston DH, Hauser CJ, Deitch EA, Rameshwar P (2001) Trauma inhibits erythroid burst-forming unit and granulocyte-monocyte colony-forming unit growth through the production of TGF-beta1 by bone marrow stroma. Ann Surg 234:224–232
Choudhry MA, Bland KI, Chaudry IH (2006) Gender and susceptibility to sepsis following trauma. Endocr Metab Immune Disord Drug Targets 6:127–135
Oberbeck R et al (2002) The effect of dehydroepiandrosterone on hemorrhage-induced suppression of cellular immune function. Intensive Care Med 28:963–968
Oberbeck R et al (2001) Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Crit Care Med 29:380–384
Frantz MC et al. (2005) Dehydroepiandrosterone restores depressed peripheral blood mononuclear cell function following major abdominal surgery via the estrogen receptors. Crit Care Med 33:1779–1786
Boelens PG et al (2002) Glutamine-enriched enteral nutrition increases HLA-DR expression on monocytes of trauma patients. J Nutr 132:2580–2586
Bastian L, Weimann A (2002) Immunonutrition in patients after multiple trauma. Br J Nutr 87 Suppl 1:S133–S134
Kotzampassi K, Giamarellos-Bourboulis EJ, Voudouris A, Kazamias P, Eleftheriadis E (2006) Benefits of a synbiotic formula (Synbiotic 2000Forte) in critically ill trauma patients: early results of a randomized controlled trial. World J Surg 30:1848–1855
Rayes N, Seehofer D, Muller AR, Hansen S, Bengmark S, Neuhaus P (2002) Influence of probiotics and fibre on the incidence of bacterial infections following major abdominal surgery—results of a prospective trial. Z Gastroenterol 40:869–876
Sugawara G et al (2006) Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg 244:706–714
Wasmuth HE et al (2004) Hyperglycemia at admission to the intensive care unit is associated with elevated serum concentrations of interleukin-6 and reduced ex vivo secretion of tumor necrosis factor-alpha. Crit Care Med 32:1109–1114
Oberbeck R (2006) Catecholamines: physiological immunomodulators during health and illness. Curr Med Chem 13:1979–1989
Keh D et al (2003) Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 167:512–520
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Flohé, S., Flohé, S.B., Schade, F.U. et al. Immune response of severely injured patients – influence of surgical intervention and therapeutic impact. Langenbecks Arch Surg 392, 639–648 (2007). https://doi.org/10.1007/s00423-007-0203-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00423-007-0203-4